New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
06:08 EDTMS, WPPGY, IPG, GS, PUBGY, CVX, XOM, RDS.A, BPOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Exporting the U.S. shale energy revolution overseas is giving the U.S. a significant competitive advantage. While there are huge shale deposits outside of North America, oil companies are running into obstacles as they try to replicate the U.S. experience on other continents. The result is that significant overseas shale energy production could be a decade away, the Wall Street Journal reports...Three major ad firms, WPP (WPPGY), Publicis Groupe (PUBGY) and Interpublic Group (IPG), are revising down their projections for 2013 global ad spending growth, citing economic troubles in Europe and lackluster conditions in the U.S., among other factors, the Wall Street Journal reports...REUTERS: Wall Street banks, including Morgan Stanley (MS) and Goldman Sachs (GS), are looking to help offshore clients sidestep new U.S. rules designed to safeguard the world's $640T over-the-counter derivatives market, taking advantage of an exemption that risks undermining U.S. regulators' efforts, Reuters reports...The U.K.s Public Accounts Committee called on the government to crack down on multinational companies that make substantial sales in Britain but pay little tax there, Reuters reports...BLOOMBERG: China may maintain its annual economic growth target at 7.5% next year in a sign the new leadership headed by Xi Jinping wont tolerate a bigger slowdown from the lowest goal since 2004, Bloomberg reports...Hedge funds increased bullish bets on commodities by the most since August as evidence that China is accelerating outweighed concern that U.S. lawmakers have yet to resolve an impasse over automatic spending cuts and tax rises, Bloomberg reports.
News For A;CVX;BP;XOM;WPPGY;PUBGY;IPG;MS;GS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:01 EDTCVX, BPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:46 EDTMSMPLX enters common unit sales agreement for up to $500M
Subscribe for More Information
09:36 EDTCVXActive equity options trading on open
Subscribe for More Information
09:20 EDTCVXW.R. Grace, Chevron JV to build catalysts plant in Lake Charles, LA
Subscribe for More Information
08:12 EDTBPBP downgraded to Sell from Neutral at Goldman
Goldman downgraded BP to Sell based on limited upstream growth, a slowdown in asset disposals, and ongoing overhang from Macondo.
07:56 EDTCVXKosmos provides update on Mauritania drilling
Subscribe for More Information
07:23 EDTCVXChevron downgraded to Sell from Neutral at Goldman
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:44 EDTBP, XOM, CVXEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
May 14, 2015
06:04 EDTGS, MSUnivision IPO could launch 'in weeks,' NY Post reports
Subscribe for More Information
May 13, 2015
12:13 EDTGSGoldman Sachs management to meet with MKM Partners
Subscribe for More Information
09:32 EDTMSMorgan Stanley fined $2M by FINRA for short interest reporting, rule violations
FINRA announced that it has fined Morgan Stanley & Co. LLC $2M for short interest reporting and short sale rule violations that spanned a period of more than six years, and for failing to implement a supervisory system reasonably designed to detect and prevent such violations. FINRA found that Morgan Stanley, over several years, failed to completely and accurately report its short interest positions in certain securities involving billions of shares. FINRA also found that the firm's supervisory system was deficient because it failed to detect and prevent these violations over an extended period of time. FINRA found that over a seven-year period, Morgan Stanley included positions from the accounts of non-broker-dealer affiliates in a number of aggregation units when determining each unit's net position. FINRA also found that the firm's supervisory system was not reasonably designed to detect and prevent such violations. In concluding this settlement, Morgan Stanley neither admitted nor denied the charges, but consented to the entry of FINRA's findings.
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
14:13 EDTMS, GSBove says it may be time to buy bank stocks
Subscribe for More Information
07:48 EDTMS, GSStandard & Poor's to hold a summit
Subscribe for More Information
07:34 EDTGSGoldman must pay $80M plus interest to National Australia Bank, Reuters reports
Goldman Sachs was recently ordered by an arbitration panel under the Financial Industry Regulatory Authority to pay $80M, plus interest, to the National Australia Bank over the sale of mortgage-linked securities, said Reuters, citing a court filing. Reference Link
05:38 EDTBPTechnip awarded lump sum project by BP Exploration & Production
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use